Citalopram and Azithromycin Co-Prescription Guidelines
Introduction to Safety Concerns
- The American College of Cardiology and other guideline societies recommend careful cardiac monitoring when co-prescribing citalopram and azithromycin due to the additive risk of QT interval prolongation, particularly in patients with pre-existing cardiac risk factors 1
Primary Safety Concern: QT Interval Prolongation
- Azithromycin is a documented cause of QT prolongation, serious arrhythmias, and increased risk for sudden death, with advanced age and female sex as additional risk factors 1
- Citalopram also contributes to QT prolongation, particularly in patients with other cardiac risk factors 1
High-Risk Patients Who Should Avoid This Combination
- Patients with a baseline QTc interval ≥ 500 ms should avoid this combination due to increased risk of cardiac arrhythmias 1
- Patients with known congenital long-QT syndrome, concurrent use of other QT-prolonging medications, uncorrected electrolyte abnormalities, advanced age, or pre-existing cardiac conditions should also avoid this combination 1, 2
Required Pre-Treatment Assessment
- A baseline ECG should be obtained to measure QTc interval before prescribing this combination, and any electrolyte abnormalities should be corrected 1, 2
- Hepatic and renal function should be assessed, as impairment may increase drug levels 2
Monitoring During Treatment
- Patients taking both medications should be monitored for cardiac symptoms, including palpitations, syncope, or dizziness, and repeat ECGs should be considered in high-risk patients 1
- The combination should be discontinued immediately if QTc exceeds 500 ms 1
Alternative Antibiotic Options
- Amoxicillin and doxycycline are alternative antibiotics without QT prolongation effects that can be considered if the cardiac risk is deemed unacceptable 3